Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Talimogene Laherparepvec (Talimogene Laherparepvec) With Neoadjuvant Chemotherapy and Radiation in Adenocarcinoma of the Rectum

NCT03300544 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03300544
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03300544 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Talimogene Laherparepvec (Talimogene Laherparepvec) With Neoadjuvant Chemotherapy and Radiation in Adenocarcinoma of the Rectum
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Terminated
Start date
May 14, 2019
Completion date
March 22, 2022
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced rectal adenocarcinoma, metastatic rectal adenocarcinoma, rectal adenocarcinoma, stage iii rectal cancer ajcc v7, stage iiia rectal cancer ajcc v7, stage iiib rectal cancer ajcc v7, stage iiic rectal cancer ajcc v7, stage iv rectal cancer ajcc v7, stage iva rectal cancer ajcc v7, stage ivb rectal cancer ajcc v7